Ohgaki, H. & Kleihues, P. Epidemiology and etiology of gliomas. Acta Neuropathol. 109, 93–108 (2005).
McLendon, R. et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061–1068 (2008).
Broekman, M. L. et al. Multidimensional communication in the microenvirons of glioblastoma. Nat. Rev. Neurol. 14, 482–495 (2018).
Article PubMed PubMed Central Google Scholar
Roesch, S., Rapp, C., Dettling, S. & Herold-Mende, C. When immune cells turn bad — tumor-associated microglia/macrophages in glioma. Int. J. Mol. Sci. 19, 436 (2018).
Article PubMed PubMed Central Google Scholar
Stupp, R. et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10, 459–466 (2009).
Article CAS PubMed Google Scholar
Galanis, E. et al. Clinical outcome of gliosarcoma compared with glioblastoma multiforme: North Central Cancer Treatment Group results. J. Neurosurg. 89, 425–430 (1998).
Article CAS PubMed Google Scholar
Johann, P., Lenz, D. & Ries, M. The drug development pipeline for glioblastoma — a cross sectional assessment of the FDA Orphan Drug Product designation database. PLoS ONE 16, e0252924 (2021).
Article CAS PubMed PubMed Central Google Scholar
Nozhat, Z. et al. Advanced biomaterials for human glioblastoma multiforme (GBM) drug delivery. Biomater. Sci. 11, 4094–4131 (2023).
Article CAS PubMed Google Scholar
Weller, M. et al. Vaccine-based immunotherapeutic approaches to gliomas and beyond. Nat. Rev. Neurol. 13, 363–374 (2017).
Article CAS PubMed Google Scholar
Kong, Z., Wang, Y. & Ma, W. Vaccination in the immunotherapy of glioblastoma. Hum. Vaccines Immunother. 14, 255–268 (2018).
Keskin, D. B. et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature 565, 234–239 (2019).
Article CAS PubMed Google Scholar
Hilf, N. et al. Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature 565, 240–245 (2019).
Article CAS PubMed Google Scholar
Jackson, C. M., Choi, J. & Lim, M. Mechanisms of immunotherapy resistance: lessons from glioblastoma. Nat. Immun. 20, 1100–1109 (2019).
Buckland, B. C. The process development challenge for a new vaccine. Nat. Med. 11, S16–S19 (2005).
Article CAS PubMed Google Scholar
Ulmer, J. B., Valley, U. & Rappuoli, R. Vaccine manufacturing: challenges and solutions. Nat. Biotechnol. 24, 1377–1383, (2006).
Article CAS PubMed Google Scholar
Kocarnik, J. M. et al. Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. JAMA Oncol. 8, 420–444 (2022).
The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Oncol. 23, 27–52, (2022).
Bagley, S. J. et al. Glioblastoma clinical trials: current landscape and opportunities for improvement. Clin. Cancer Res. 28, 594–602 (2022).
Article PubMed PubMed Central Google Scholar
Belykh, E. et al. Blood-brain barrier, blood-brain tumor barrier, and fluorescence-guided neurosurgical oncology: delivering optical labels to brain tumors. Front. Oncol. 10, 739 (2020).
Article PubMed PubMed Central Google Scholar
Yin, Y. et al. In situ transforming RNA nanovaccines from polyethylenimine functionalized graphene oxide hydrogel for durable cancer immunotherapy. Nano Lett. 21, 2224–2231 (2021).
Article CAS PubMed Google Scholar
Conniot, J. et al. Immunization with mannosylated nanovaccines and inhibition of the immune-suppressing microenvironment sensitizes melanoma to immune checkpoint modulators. Nat. Nanotechnol. 14, 891–901 (2019).
Article CAS PubMed Google Scholar
Bergquist, B., Mahaley, M. S., Steinbok, P. & Dudka, L. F. Treatment of a brain tumor with BCG cell wall preparation. Surg. Neurol. 13, 197–201 (1980).
Mahaley, M. S. et al. Immunobiology of primary intracranial tumors. Part 7: active immunization of patients with anaplastic human glioma cells: a pilot study. J. Neurosurg. 59, 201–207 (1983).
Agnihotri, S., Yang, K., Mitchell, D. A. & Rich, J. N. A vaccine for glioma. Nat. Cancer 2, 584–586 (2021).
Article CAS PubMed Google Scholar
Abd-Aziz, N. & Poh, C. L. Development of peptide-based vaccines for cancer. J. Oncol. 2022, 9749363 (2022).
Article PubMed PubMed Central Google Scholar
Mahdavi, A. & Monk, B. J. Vaccines against human papillomavirus and cervical cancer: promises and challenges. Oncologist 10, 528–538, (2005).
Article CAS PubMed Google Scholar
Brun, S. N. et al. Survivin as a therapeutic target in Sonic hedgehog-driven medulloblastoma. Oncogene 34, 3770–3779 (2015).
Article CAS PubMed Google Scholar
Fenstermaker, R. A. et al. Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma. Cancer Immunol. Immunother. 65, 1339–1352 (2016).
Article CAS PubMed PubMed Central Google Scholar
Mazur, J., Roy, K. & Kanwar, J. R. Recent advances in nanomedicine and survivin targeting in brain cancers. Nanomedicine 13, 105–137 (2018).
Article CAS PubMed Google Scholar
Swartz, A. M., Batich, K. A., Fecci, P. E. & Sampson, J. H. Peptide vaccines for the treatment of glioblastoma. J. Neurooncol. 123, 433–440 (2015).
Article CAS PubMed Google Scholar
Purcell, A. W., McCluskey, J. & Rossjohn, J. More than one reason to rethink the use of peptides in vaccine design. Nat. Rev. Drug Discov. 6, 404–414, (2007).
Article CAS PubMed Google Scholar
Kuai, R., Ochyl, L. J., Bahjat, K. S., Schwendeman, A. & Moon, J. J. Designer vaccine nanodiscs for personalized cancer immunotherapy. Nat. Mat. 16, 489–496 (2017).
Schumacher, T. N. & Schreiber, R. D. Neoantigens in cancer immunotherapy. Science 348, 69–74 (2015).
Article CAS PubMed Google Scholar
Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415–421 (2013).
Article CAS PubMed PubMed Central Google Scholar
Lawrence, M. S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214–218 (2013).
Article CAS PubMed PubMed Central Google Scholar
De Waele, J. et al. A systematic review on poly(I:C) and poly-ICLC in glioblastoma: adjuvants coordinating the unlocking of immunotherapy. J. Exp. Clin. Cancer Res. 40, 213 (2021).
Article PubMed PubMed Central Google Scholar
Blass, E. & Ott, P. A. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat. Rev. Clin. Oncol. 18, 215–229 (2021).
Article PubMed PubMed Central Google Scholar
Lee-Chang, C. & Lesniak, M. S. Next-generation antigen-presenting cell immune therapeutics for gliomas. J. Clin. Invest. 133, e163449 (2023).
Article CAS PubMed PubMed Central Google Scholar
Datsi, A. & Sorg, R. V. Dendritic cell vaccination of glioblastoma: road to success or dead end. Front. Immunol. 12, 770390 (2021).
Article CAS PubMed PubMed Central Google Scholar
Lin, M. J. et al. Cancer vaccines: the next immunotherapy frontier. Nat. Cancer 3, 911–926 (2022).
留言 (0)